Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AlloEx in Stroke
NCT05158101Phase 1Recruiting
- Sponsor
- The Foundation for Orthopaedics and Regenerative Medicine
- Start
- Feb 2022
- Primary completion
- Feb 2028
- Modality
- Lipid-based Nanoparticles, Cell Therapies
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of AlloEx in stroke, sponsored by The Foundation for Orthopaedics and Regenerative Medicine. Primary endpoint: Adverse Events at 4 years. Started Feb 2022; status: recruiting.
02
Drugs
AlloEx
03
Conditions
stroke
Beyond the preview
Go deeper on NCT05158101.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05158101.